Niagen Bioscience annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Niagen Bioscience's operating margin was 12.58% for fiscal 2025.
View full Niagen Bioscience company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 12.58% | +4.82 pp |
| 2024 | 2024-12-31 | 7.76% | +14.46 pp |
| 2023 | 2023-12-31 | −6.70% | +19.15 pp |
| 2022 | 2022-12-31 | −25.85% | +14.28 pp |
| 2021 | 2021-12-31 | −40.14% | −6.63 pp |
| 2020 | 2020-12-31 | −33.50% | +34.11 pp |
| 2019 | 2019-12-31 | −67.62% | +37.50 pp |
| 2018 | 2018-12-31 | −105.12% | −27.87 pp |
| 2017 | 2017-12-30 | −77.25% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.35% | −7.89 pp |
| Q1 2026 | 2026-03-31 | 5.01% | −10.65 pp |
| Q4 2025 | 2025-12-31 | 12.07% | −12.34 pp |
| Q3 2025 | 2025-09-30 | 12.46% | +6.20 pp |
| Q2 2025 | 2025-06-30 | 10.24% | +11.36 pp |
| Q1 2025 | 2025-03-31 | 15.66% | +18.96 pp |
| Q4 2024 | 2024-12-31 | 24.42% | +25.21 pp |
| Q3 2024 | 2024-09-30 | 6.26% | +12.15 pp |
| Q2 2024 | 2024-06-30 | −1.13% | +10.27 pp |
| Q1 2024 | 2024-03-31 | −3.30% | +5.43 pp |
| Q4 2023 | 2023-12-31 | −0.79% | +6.08 pp |
| Q3 2023 | 2023-09-30 | −5.88% | +12.08 pp |
| Q2 2023 | 2023-06-30 | −11.40% | +26.78 pp |
| Q1 2023 | 2023-03-31 | −8.72% | +36.07 pp |
| Q4 2022 | 2022-12-31 | −6.88% | +23.06 pp |
| Q3 2022 | 2022-09-30 | −17.96% | +33.12 pp |
| Q2 2022 | 2022-06-30 | −38.17% | −6.79 pp |
| Q1 2022 | 2022-03-31 | −44.80% | +5.34 pp |
| Q4 2021 | 2021-12-31 | −29.93% | +9.44 pp |
| Q3 2021 | 2021-09-30 | −51.08% | −21.49 pp |
| Q2 2021 | 2021-06-30 | −31.38% | −7.26 pp |
| Q1 2021 | 2021-03-31 | −50.14% | −9.08 pp |
| Q4 2020 | 2020-12-31 | −39.37% | +28.32 pp |
| Q3 2020 | 2020-09-30 | −29.59% | +27.56 pp |
| Q2 2020 | 2020-06-30 | −24.12% | +40.56 pp |
| Q1 2020 | 2020-03-31 | −41.06% | +42.26 pp |
| Q4 2019 | 2019-12-31 | −67.69% | +23.19 pp |
| Q3 2019 | 2019-09-30 | −57.15% | +48.71 pp |
| Q2 2019 | 2019-06-30 | −64.68% | +37.04 pp |
| Q1 2019 | 2019-03-31 | −83.32% | +44.58 pp |
| Q4 2018 | 2018-12-31 | −90.88% | −10.34 pp |
| Q3 2018 | 2018-09-30 | −105.86% | −53.66 pp |
| Q2 2018 | 2018-06-30 | −101.72% | −38.89 pp |
| Q1 2018 | 2018-03-31 | −127.90% | +3.30 pp |
| Q4 2017 | 2017-12-30 | −80.54% | +14.14 pp |
| Q3 2017 | 2017-09-30 | −52.20% | +3.72 pp |
| Q2 2017 | 2017-07-01 | −62.83% | −48.41 pp |
| Q3 2011 | 2011-10-01 | −131.20% | — |
| Q2 2011 | 2011-07-02 | −94.68% | — |
| Q3 2010 | 2010-10-02 | −55.92% | — |
| Q2 2010 | 2010-07-03 | −14.42% | — |
Over the last five reported fiscal years, Niagen Bioscience's operating margin increased from −33.50% to 12.58%, a change of +46.08 percentage points. The latest reported quarter, Q2 2026, shows 2.35%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Niagen Bioscience filings at SEC.gov ↗